Navidea Biopharmaceuticals, Inc. Navidea Biopharmaceuticals, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Grant Funding
  • Pipeline
  • News & Media
    • Press Releases
    • Events
    • In the News
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Events
  • In the News

Navidea Biopharmaceuticals Prices $6.0 Million Public Offering of Common Stock

Jun 13, 2019

Navidea Biopharmaceuticals Announces Proposed Public Offering of Common Stock

Jun 13, 2019

Navidea Biopharmaceuticals Regains Direct Control of Intellectual Property

Jun 13, 2019

Navidea Biopharmaceuticals Reports First Quarter 2019 Financial Results

May 8, 2019

Navidea Biopharmaceuticals Schedules First Quarter 2019 Earnings Conference Call and Business Update

May 1, 2019

Navidea Biopharmaceuticals Announces Comparative Study to Evaluate the Potential Utility of Tilmanocept In Patients with Tuberculosis (“TB”)

Apr 26, 2019

Navidea Biopharmaceuticals Announces Reverse Stock Split

Apr 19, 2019

Navidea Biopharmaceuticals Receives FDA Feedback Regarding Rheumatoid Arthritis Clinical Trial Design and Provides Business Updates

Apr 8, 2019

Navidea Biopharmaceuticals Data to be Presented at Society of Nuclear Medicine and Molecular Imaging Annual Meeting

Apr 2, 2019

Navidea Biopharmaceuticals Announces Stock Purchase Agreement; Other Business Updates

Mar 22, 2019
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...37
    © 2021 Navidea Biopharmaceuticals, Inc. All Rights Reserved.
    Twitter linkedin Facebook
    Privacy Policy Disclaimer Sitemap